医药品·生物科技的合资企业交易 (2016～2024年)

本报告提供全球医药品·生物科技市场上合资企业交易的缔结状况相关分析，彙整整体交易数量的转变和预测 (2016～2024年)，近几年的代表性交易案例，主要企业 (全25公司) 的交易缔结动向，各技术·各治疗领域达成交易的动向等资讯，为您概述为以下内容。

目录

摘要整理

第1章 简介

第2章 合资企业交易趋势

• 简介
• 合资企业交易定义
• 合资企业交易趋势 (2016年以后)
  • 合资企业交易趋势:各年度 (2016～2024年)
  • 合资企业交易趋势:各开发阶段 (2016～2024年)
  • 合资企业交易趋势:各产业领域 (2016～2024年)
  • 合资企业交易趋势:各治疗领域 (2016～2024年)
  • 合资企业交易趋势:各技术种类 (2016～2024年)
  • 合资企业交易趋势:最活跃的企业的情况 (2016～2024年)
• 签订合资企业的联盟交易的理由
• 合资企业交易的未来性

第3章 合资企业的交易结构:概要

• 简介
• 合资企业契约结构

第4章 合资企业的主要的交易

• 简介
• 前几名的合资企业交易 (以金额为准)

第5章 合资企业交易:最活跃的交易缔结25企业

• 简介
• 合资企业交易:最活跃的交易缔结25企业

第6章 合资企业交易:契约的明细

• 简介
• 合资企业契约 (2016～2024年)
• 交易明细
• 交易明细:合资企业的交易缔结，企业名 (A～Z)
• 交易明细:合资企业的交易缔结，各治疗领域
• 交易明细:合资企业的交易缔结，各技术种类

关于Wildwood Ventures

Joint Venture Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter joint venture deals.

Fully revised and updated, the report provides details of joint venture deals from 2016 to 2024.

The report provides access to joint venture deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of joint venture deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual joint venture contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of joint venture dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in joint venture as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of joint venture deals.

Chapter 4 provides a review of the leading joint venture deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active joint venture dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of joint venture deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the joint venture deal.

The deal directory includes a comprehensive listing of all joint venture deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in joint venture dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about joint venture alliances.

Key benefits

Joint Venture Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse joint venture deals
• Benchmark analysis - identify market value of transactions
• Financials terms
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Joint Venture Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the joint venture trends and structure of deals entered into by leading biopharma companies worldwide.

Joint Venture Deals in Pharmaceuticals and Biotechnology includes:

• Trends in joint venture dealmaking in the biopharma industry
• Overview of joint venture deal structure
• Directory of joint venture deal records covering pharmaceutical and biotechnology
• The leading joint venture deals by value
• Most active joint venture dealmakers
• The leading joint venture partnering resources

In Joint Venture Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Joint Venture Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for joint venture deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in joint venture dealmaking

• 2.1. Introduction
• 2.2. Definition of joint venture deal
• 2.3. Trends in joint venture deals since 2016
  • 2.3.1. Joint venture dealmaking by year, 2016-2024
  • 2.3.2. Joint venture dealmaking by phase of development, 2016-2024
  • 2.3.3. Joint venture dealmaking by industry sector, 2016-2024
  • 2.3.4. Joint venture dealmaking by therapy area, 2016-2024
  • 2.3.5. Joint venture dealmaking by technology type, 2016-2024
  • 2.3.6. Joint venture dealmaking by most active company, 2016-2024
• 2.4. Reasons for entering into joint venture partnering deals
• 2.5. The future of joint venture deals

Chapter 3 - Overview of joint venture deal structure

• 3.1. Introduction
• 3.2. Joint venture agreement structure

Chapter 4 - Leading joint venture deals

• 4.1. Introduction
• 4.2. Top joint venture deals by value

Chapter 5 - Top 25 most active joint venture dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active joint venture dealmakers

Chapter 6 - Joint venture deals including contracts directory

• 6.1. Introduction
• 6.2. Joint venture deals with contracts 2016-2024
• Deal directory
• Deal directory - joint venture dealmaking by companies A-Z
• Deal directory - joint venture dealmaking by therapy area
• Deal directory - joint venture dealmaking by technology type

About Wildwood Ventures

• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of joint venture deal
• Figure 2: Trends in joint venture deal announcements, 2016-2024
• Figure 3: Joint venture deals signed at each phase of development, 2016-2024
• Figure 4: Joint venture deals by industry sector, 2016-2024
• Figure 5: Joint venture deals by therapy area, 2016-2024
• Figure 6: Joint venture deals by technology type, 2016-2024
• Figure 7: Top 25 most active joint venture dealmakers, 2016-2024
• Figure 8: Top joint venture deals by value, 2016-2024
• Figure 9: Most active joint venture dealmakers, 2016-2024